MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$3,055K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from exercise of warran...
Accrued expenses and other curre...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Net loss
Prepaid expenses and other asset...
Accounts payable
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-7,635
-12,845
15,552
-35,036
Depreciation and amortization
8
8
9
22
Stock-based compensation
436
380
459
303
Change in fair value of warrant liability
7
-10,770
-23,410
17,632
Loss on extinguishment of warrant liabilities
-
-
-614
-
Loss on issuance of warrant liabilities
0
-15,158
0
-12,812
Operating lease, net
-150
134
-139
-3
Transaction costs allocated to warrant liabilities
2
693
-330
-1,258
Prepaid expenses and other assets
816
-163
-374
-337
Accounts payable
-238
1,067
1,287
-1,483
Accrued expenses and other current liabilities
1,729
-99
218
-549
Net cash used in operating activities
-6,657
-6,111
-5,366
-7,223
Purchase of fixed assets
-
-
0
0
Net cash used in investing activities
0
0
0
0
Payment of tax liability for vested restricted stock units
-
-
8
0
Net cash used in investing activities
0
-
-
-
Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs
-4
7,612
7,089
5,264
Proceeds from exercise of warrants
2,817
0
406
1,111
Proceeds from issuance of common stock under at-the-market equity program, net of transaction costs
800
-
-
-
Net cash provided by financing activities
3,613
7,612
7,487
6,375
Effect of exchange rate changes on cash and cash equivalents
-11
-62
54
-6
Net increase (decrease) in cash and cash equivalents
-3,055
1,439
2,175
-854
Cash and cash equivalents - beginning of period
10,317
8,878
6,703
4,278
Cash and cash equivalents - end of period
7,262
10,317
8,878
6,703
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
warrants
$2,817K
(28070.00%↑ Y/Y)
Proceeds from issuance of
common stock under...
$800K
Net cash provided by
financing activities
$3,613K
(-73.08%↓ Y/Y)
Canceled cashflow
$4K
Net increase
(decrease) in cash and cash...
-$3,055K
(-193.17%↓ Y/Y)
Canceled cashflow
$3,613K
Accrued expenses and
other current...
$1,729K
(396.84%↑ Y/Y)
Stock-based compensation
$436K
(-51.66%↓ Y/Y)
Depreciation and
amortization
$8K
(-86.44%↓ Y/Y)
Change in fair value of
warrant liability
$7K
(100.04%↑ Y/Y)
Transaction costs allocated
to warrant...
$2K
(-99.93%↓ Y/Y)
Proceeds from sale of
common stock,...
-$4K
(-100.03%↓ Y/Y)
Net cash used in
operating activities
-$6,657K
(34.39%↑ Y/Y)
Canceled cashflow
$2,182K
Effect of exchange rate
changes on cash and cash...
-$11K
(-466.67%↓ Y/Y)
Net loss
-$7,635K
(45.76%↑ Y/Y)
Prepaid expenses and
other assets
$816K
(-45.71%↓ Y/Y)
Accounts payable
-$238K
(-115.60%↓ Y/Y)
Operating lease, net
-$150K
(-229.31%↓ Y/Y)
Buy us a coffee
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)